^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Excerpt:
We aimed to investigate the prevalence, clinicopathologic characteristics, and functional relevance of novel HER2 mutations in breast cancer....neratinib produced a strong inhibition of colony formation for all eight mutations, including K753E and L755S.
DOI:
10.1158/1078-0432.CCR-15-3036